Cytokeratin 20 Antibody (E-9): sc-271183

Cytokeratin 20 Antibody (E-9) is a mouse monoclonal IgG1 antibody that detects Cytokeratin 20 (CK20) protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). CK20 Antibody (E-9) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CK20, a member of the cytokeratin family, is primarily located in the cytoplasm of epithelial cells, particularly in the gastrointestinal tract, where CK20 is abundantly expressed in goblet cells and enterocytes. Such localization plays a significant role in maintaining the structural integrity and function of epithelial tissues, which are essential for barrier formation and nutrient absorption. CK20 serves as a valuable marker for pancreatic and colorectal cancers, aiding in the differentiation of various carcinomas, including distinguishing renal oncocytomas from renal cell carcinomas. Anti-CK20 antibody (E-9) effectively identifies CK20 across multiple applications, making this tool indispensable for researchers and clinicians studying epithelial cell biology and cancer pathology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 20 Antibody (E-9) References:

1. Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer.  |  Wildi, S., et al. 1999. Clin Cancer Res. 5: 2840-7. PMID: 10537351
2. Merkel cell carcinoma can be distinguished from metastatic small cell carcinoma using antibodies to cytokeratin 20 and thyroid transcription factor 1.  |  Leech, SN., et al. 2001. J Clin Pathol. 54: 727-9. PMID: 11533085
3. Cytokeratin 20 positive cells in blood of colorectal cancer patients as an unfavorable prognostic marker.  |  Kust, D., et al. 2016. Acta Clin Belg. 71: 235-43. PMID: 27144776
4. Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers.  |  Dum, D., et al. 2022. Exp Mol Pathol. 126: 104762. PMID: 35390310
5. Diagnostic Significance of Cytokeratin 20 and p53 as Adjunct Immunocytological Markers in Urine Cytology to Detect Urothelial Carcinomas: A Systematic Review Study.  |  Angel, E. 2023. Iran J Pathol. 18: 257-269. PMID: 37942190
6. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary.  |  Wauters, CC., et al. 1995. Hum Pathol. 26: 852-5. PMID: 7543441
7. Cytokeratin expression in normal and (pre)malignant head and neck epithelia: an overview.  |  van der Velden, LA., et al. 1993. Head Neck. 15: 133-46. PMID: 7680025
8. The human gene encoding cytokeratin 20 and its expression during fetal development and in gastrointestinal carcinomas.  |  Moll, R., et al. 1993. Differentiation. 53: 75-93. PMID: 8359595
9. Serum and tissue distribution of a fragment of cytokeratin 19 (cyfra 21-1) in lung cancer patients.  |  Quillien, V., et al. 1995. Anticancer Res. 15: 2857-63. PMID: 8669879
10. Keratins and the skin.  |  Fuchs, E. 1995. Annu Rev Cell Dev Biol. 11: 123-53. PMID: 8689554
11. Functional inactivation of p53 by antisense RNA induces invasive ability of lung carcinoma cells and downregulates cytokeratin synthesis.  |  Mukhopadhyay, T. and Roth, JA. 1996. Anticancer Res. 16: 1683-9. PMID: 8712687
12. Cytokeratin expression, fibrillar organization, and subtle function in liver cells.  |  Marceau, N. and Loranger, A. 1995. Biochem Cell Biol. 73: 619-25. PMID: 8714681

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Cytokeratin 20 Antibody (E-9) has 4 citations in a variety of scientific publications.

Primary antibodies like Anti-Cytokeratin 20 Antibody (E-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Cytokeratin 20 Antibody (E-9) Specifications

Alternate Product Name: KRT20

Product Clone Name: E-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ lambda light chain

Amino Acids: 39-74

Epitope Target: Cytokeratin 20

Epitope Species: human

Product Reactivity/Detection: Cytokeratin 20

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ lambda light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 4 citations in various scientific publications

Available Conjugates/Forms for Cytokeratin 20 Antibody (E-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin